Clinical Trial: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

Clinical Trial: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

Sponsor and Collaborators

Assistance Publique - Hôpitaux de Paris

Contact
Contact: Zakia Idir, PhD
+33 1 4484 1747
zakia.idir@sls.aphp.fr

Principal Investigator
Celeste Lebbe, MD, PhD Hôpital Saint-Louis, Paris, France

ClinicalTrials.gov Identifier
NCT01168050
You must be a registered member of ONA to post a comment.

April Contest

Click here to get started

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs